- Previous Close
0.0005 - Open
0.0025 - Bid 0.0010 x --
- Ask 0.0090 x --
- Day's Range
0.0025 - 0.0025 - 52 Week Range
0.0005 - 0.0845 - Volume
13,633 - Avg. Volume
3,221 - Market Cap (intraday)
4.65M - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has a collaboration agreement with SUANFARMA to develop anti-infective API through precision fermentation; and a multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients. Willow Biosciences Inc. was founded in 2019 and is headquartered in Calgary, Canada.
www.willowbio.com19
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 3D7.F
View MorePerformance Overview: 3D7.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3D7.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3D7.F
View MoreValuation Measures
Market Cap
930.06k
Enterprise Value
1.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.04
Price/Book (mrq)
0.57
Enterprise Value/Revenue
0.82
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-132.75%
Return on Assets (ttm)
-76.14%
Return on Equity (ttm)
-422.31%
Revenue (ttm)
4.66M
Net Income Avi to Common (ttm)
-6.19M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
353k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.35M